Calidi Biotherapeutics, Inc. (CLDI)
| Market Cap | 3.42M -62.7% |
| Revenue (ttm) | n/a |
| Net Income | -23.46M |
| EPS | -33.30 |
| Shares Out | 2.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,007 |
| Open | 1.320 |
| Previous Close | 1.300 |
| Day's Range | 1.280 - 1.370 |
| 52-Week Range | 1.250 - 27.840 |
| Beta | 1.33 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CLDI
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as Ne... [Read more]
Financial Performance
Financial StatementsNews
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of system...
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of syste...
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a biotechnology company pioneering the development of targeted genetic medi...
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announ...
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medi...
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medi...
Calidi receives pre-IND regulatory feedback from FDA for CLD-401
Calidi (CLDI) announced that it has received pre-IND regulatory feedback from the FDA providing alignment and clarity on Calidi’s IND-enabling preclinical plans and clinical strategy for CLD-401 prior...
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel IND enabling studies wit...
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medi...
Calidi announces online abstract acceptances at 2026 ASCO Meeting
Calidi (CLDI) Biotherapeutics announced that two abstracts showcasing the Company’s RedTail platform have been accepted for online publication at the 2026 American Society of Clinical Oncology, ASCO, ...
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medic...
Calidi provides required NYSE American disclosure
Calidi (CLDI) Biotherapeutics advised that its Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2025, contained an audit report from its Independent…
Calidi Biotherapeutics Provides Required NYSE American Disclosure
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic medic...
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medici...
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “t...
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic med...
Calidi presents new data on CLD-401 at AACR
Calidi (CLDI) Biotherapeutics will present new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on April 21 2026. The Company showcased new data…
Calidi presents new data on in situ t-cell engagers at AACR
Calidi (CLDI) Biotherapeutics presented new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on…
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic med...
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medi...
Calidi presents manufacturing process for CDI-401 at BioProcessing Summit
Calidi (CLDI) Biotherapeutics presented on its proprietary manufacturing process for CLD-401 at the BioProcessing Summit in Barcelona. RedTail is Calidi’s systemically delivered virotherapy platform d...
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic med...
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option
$12 Million of Tranche Warrants Potential Financing Within One Year From Closing $12 Million of Tranche Warrants Potential Financing Within One Year From Closing
Calidi prices 10.5M units at 50c in underwritten public offering
Calidi (CLDI) Biotherapeutics announced the pricing of its underwritten public offering of 10,519,631 units, with each unit consisting of one share of common stock, one 6 month warrant to purchase…